-$0.45 Earnings Per Share Expected for Syros Pharmaceuticals Inc (SYRS) This Quarter
Analysts expect that Syros Pharmaceuticals Inc (NASDAQ:SYRS) will post earnings per share (EPS) of ($0.45) for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Syros Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.49) and the highest is ($0.43). Syros Pharmaceuticals posted earnings per share of ($0.53) during the same quarter last year, which would indicate a positive year-over-year growth rate of 15.1%. The company is expected to announce its next earnings report on Wednesday, November 14th.
On average, analysts expect that Syros Pharmaceuticals will report full-year earnings of ($1.85) per share for the current year, with EPS estimates ranging from ($1.92) to ($1.77). For the next financial year, analysts expect that the business will post earnings of ($1.93) per share, with EPS estimates ranging from ($2.12) to ($1.67). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that that provide coverage for Syros Pharmaceuticals.
Syros Pharmaceuticals (NASDAQ:SYRS) last issued its earnings results on Friday, August 10th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.50) by $0.07. The company had revenue of $0.38 million for the quarter, compared to analysts’ expectations of $1.33 million.
A number of institutional investors have recently made changes to their positions in SYRS. BlackRock Inc. raised its holdings in Syros Pharmaceuticals by 70.4% in the second quarter. BlackRock Inc. now owns 1,583,631 shares of the company’s stock worth $16,169,000 after purchasing an additional 654,094 shares in the last quarter. ARK Investment Management LLC raised its holdings in Syros Pharmaceuticals by 19.6% in the second quarter. ARK Investment Management LLC now owns 1,799,553 shares of the company’s stock worth $18,373,000 after purchasing an additional 294,663 shares in the last quarter. Millennium Management LLC raised its holdings in Syros Pharmaceuticals by 129.3% in the second quarter. Millennium Management LLC now owns 375,466 shares of the company’s stock worth $3,834,000 after purchasing an additional 211,696 shares in the last quarter. Point72 Asset Management L.P. bought a new position in Syros Pharmaceuticals in the second quarter worth about $1,703,000. Finally, Renaissance Technologies LLC bought a new position in Syros Pharmaceuticals in the second quarter worth about $1,684,000. Institutional investors and hedge funds own 60.70% of the company’s stock.
Shares of SYRS traded down $0.27 during trading hours on Friday, reaching $7.61. 179,167 shares of the company traded hands, compared to its average volume of 187,573. The firm has a market capitalization of $400.82 million, a P/E ratio of -3.57 and a beta of -1.96. Syros Pharmaceuticals has a 12-month low of $6.30 and a 12-month high of $17.50.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML.
Further Reading: Investing in Dividend Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.